Transformational
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
About iVeena
iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing non-surgical, non-invasive, pharmacologic innovations. These novel disease modifying interventions address significant unmet needs in the treatment of corneal disease and myopic conditions.
What We Do
Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and IVMED-85 for myopia.
News
-
October 26, 2023SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, ..
-
August 24, 2022iVeena enters into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic ..
-
November 10, 2021SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, announces successful ..